Oragenics Statistics
Total Valuation
Oragenics has a market cap or net worth of $3.53 million. The enterprise value is $3.59 million.
Important Dates
The next estimated earnings date is Friday, November 15, 2024, after market close.
| Earnings Date | Nov 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Oragenics has 11.26 million shares outstanding. The number of shares has increased by 58.10% in one year.
| Shares Outstanding | 11.26M |
| Shares Change (YoY) | +58.10% |
| Shares Change (QoQ) | +29.55% |
| Owned by Insiders (%) | 4.54% |
| Owned by Institutions (%) | 3.92% |
| Float | 9.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 129.03 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 480.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.17
| Current Ratio | 1.17 |
| Quick Ratio | 0.97 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -557.03 |
Financial Efficiency
Return on equity (ROE) is -454.72% and return on invested capital (ROIC) is -277.96%.
| Return on Equity (ROE) | -454.72% |
| Return on Assets (ROA) | -219.89% |
| Return on Capital (ROIC) | -277.96% |
| Revenue Per Employee | $1,493 |
| Profits Per Employee | -$3.90M |
| Employee Count | 5 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -91.72% in the last 52 weeks. The beta is 0.48, so Oragenics's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | -91.72% |
| 50-Day Moving Average | 0.49 |
| 200-Day Moving Average | 1.44 |
| Relative Strength Index (RSI) | 37.30 |
| Average Volume (20 Days) | 522,275 |
Short Selling Information
The latest short interest is 197,981, so 1.76% of the outstanding shares have been sold short.
| Short Interest | 197,981 |
| Short Previous Month | 174,440 |
| Short % of Shares Out | 1.76% |
| Short % of Float | 2.00% |
| Short Ratio (days to cover) | 0.55 |
Income Statement
In the last 12 months, Oragenics had revenue of $7,466 and -$19.52 million in losses. Loss per share was -$6.02.
| Revenue | 7,466 |
| Gross Profit | -13.37M |
| Operating Income | -19.66M |
| Pretax Income | -19.52M |
| Net Income | -19.52M |
| EBITDA | -19.64M |
| EBIT | -19.66M |
| Loss Per Share | -$6.02 |
Full Income StatementBalance Sheet
| Cash & Cash Equivalents | 1.35M |
| Total Debt | n/a |
| Net Cash | 1.35M |
| Net Cash Per Share | $0.12 |
| Equity (Book Value) | 1.33M |
| Book Value Per Share | -0.05 |
| Working Capital | 235,646 |
Full Balance SheetCash Flow
| Operating Cash Flow | -7.21M |
| Capital Expenditures | n/a |
| Free Cash Flow | -7.21M |
| FCF Per Share | -$0.64 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -263,285.20% |
| Pretax Margin | -261,401.51% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -95,775.77% |